Salud financiera de hoja de balance de Emergent BioSolutions
Salud financiera controles de criterios 2/6
Emergent BioSolutions tiene unos fondos propios totales de $956.3M y una deuda total de $919.9M, lo que sitúa su ratio deuda/fondos propios en 96.2%. Sus activos y pasivos totales son $2.2B y $1.2B respectivamente.
Información clave
132.5%
Ratio deuda-patrimonio
US$860.20m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$111.70m |
| Patrimonio | US$649.30m |
| Total pasivo | US$1.17b |
| Activos totales | US$1.82b |
Actualizaciones recientes sobre salud financiera
Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05
Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Recent updates
New CEO Appointment A Clear Positive For Emergent BioSolutions
Feb 27Emergent BioSolutions: Q3 Numbers Leave Work To Be Done
Dec 18Emergent BioSolutions: Meaningful Debt, But Narcan Should Grow
Nov 23Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
Aug 23Financial Woes Darken Emergent BioSolutions' Outlook (Rating Downgrade)
Aug 14Emergent BioSolutions: Making A Big Bet On Narcan
Jul 21An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 30% Undervalued
Jun 22Is Emergent BioSolutions (NYSE:EBS) Using Too Much Debt?
Apr 05Emergent Biosolutions Q4 2022 Earnings Preview
Feb 24An Intrinsic Calculation For Emergent BioSolutions Inc. (NYSE:EBS) Suggests It's 39% Undervalued
Feb 16Emergent BioSolutions to offload travel health business to Bavarian Nordic for $380M
Feb 15Emergent BioSolutions: No Change To Thesis Following Latest Numbers, Recent Developments
Dec 07Emergent plunges 30% on quarterly earnings miss, lowers full-year guidance
Nov 09Emergent doses first participant in Phase 1 trial for Lassa virus vaccine
Sep 06Emergent BioSolutions: Now Long Through Sale Of October Put Spreads
Aug 24A Look At The Fair Value Of Emergent BioSolutions Inc. (NYSE:EBS)
Aug 13Additional 135M COVID-19 vaccine doses destroyed at Emergent BioSolutions Baltimore plant
Aug 12Emergent BioSolutions misses on top and bottom lines as it swings to quarterly loss
Aug 01Moderna 2.0: 3 Stocks To Play The Potential Monkeypox Pandemic
Jul 26Emergent BioSolutions (NYSE:EBS) Takes On Some Risk With Its Use Of Debt
Jul 26Kamada inks $11.4 M supply deal for chickenpox preventive antibody Varizig
Jul 06Emergent BioSolutions: A Top Pick For The Monkeypox Outbreak
May 29Emergent BioSolutions Inc. (NYSE:EBS) Shares Could Be 37% Below Their Intrinsic Value Estimate
May 12Emergent BioSolutions (NYSE:EBS) Has A Pretty Healthy Balance Sheet
Apr 24Análisis de la situación financiera
Pasivos a corto plazo: EBSLos activos a corto plazo ($777.7M) de la empresa superan a sus pasivos a corto plazo ($693.2M).
Pasivo a largo plazo: EBSLos activos a corto plazo ($777.7M) superan a sus pasivos a largo plazo ($529.3M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de EBS (86.9%) se considera alta.
Reducción de la deuda: EBSha pasado de 1.4% a 96.2% en los últimos 5 años.
Cobertura de la deuda: EBS's operating cash flow es negativo, por lo que la deuda no está bien cubierta.
Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de EBS sobre su deuda están bien cubiertos por el EBIT.